Thomas Schmittgen, Ph.D.

Thomas Schmittgen

Professor and Chair and the V. Ravi Chandran Professor of Pharmaceutical Sciences


OFFICE: Cancer Genetics Research Complex, Room 459


PHONE: 352-273-8028

CV: Link to CV



  • Ph.D., Pharmaceutics, The Ohio State University, Columbus, Ohio
  • B.S., Pharmacy, The Ohio State University, Columbus, Ohio

Biographical Sketch

Tom Schmittgen, Ph.D., joined the College of Pharmacy as a professor in the department of pharmaceutics. He assumed the role of department chair of pharmaceutics on Aug. 1, 2018. He is supported by the University of Florida’s Preeminence program with a focus on cancer therapeutics and drug discovery and development. He earned an undergraduate degree in pharmacy and graduate degrees in pharmaceutics from The Ohio State University and was a National Research Service Award (NIH) postdoctoral fellow at the University of Southern California from 1992-95. He served on the faculty at Washington State University College of Pharmacy before returning to Ohio State in 2002. His research focuses on noncoding RNAs and cancer, with emphasis on the use of microRNAs as therapeutic or diagnostic agents. A paper he co-authored in 2001 describing the relative method of gene quantification has been cited over 36,000 times and was recently ranked by the international journal Nature as the 21st most-cited scientific article of all time. His lab was the first to establish a link between altered microRNA expression in pancreatic cancer and the intellectual property resulting from this work is the basis of the product miRInform Pancreas™, a biomarker of early pancreatic cancer development. Recently, he has focused his attention on the development of microvesicles as targeted drug delivery systems for the treatment of cancer.


  • American Association for Cancer Research
  • American Association of Pharmaceutical Scientists
  • American Association of Colleges of Pharmacy
  • American Association for the Advancement of Science

Research Interests

  • Cancer therapeutics
  • Exosomes as targeted drug delivery systems
  • Role of noncoding RNAs in cancer initiation and progression

Selected Publications

  • microRNA profile in the KC mouse model of pancreatic adenocarcinoma, generation of triple gene knockout is embryonic lethal. Azevedo-Pouly, A.C.P., Sutaria, D.S., Jiang, J., Elgamal, O.A., Allard, D., Grippo, P., Coppola, E. and Schmittgen, T.D., Functional & Integrative Genomics, 2016 Aug 19.
  • Kim, J.H., Park, J.K., Jiang, J., Badawi, M., Mo, X., Nagorney, D.M., Roberts, L.R. and Schmittgen, T.D. Anti-Invasion and anti-migration effects of miR-199a-3p in hepatocellular carcinoma are due in part to targeting CD151. Int. J. Oncol., 2016 Nov;49(5):2037-2045.
  • Han, S., Gonzalo, D.H., Feely, M., Behrns, K.E., McDowell, L.L., Delitto, D., Beveridge, M., Zhang, D’Y., Thomas, R., Trevino, J.G., Schmittgen, T.D., and Hughes, S.J. Co-culture induced miR-205 and miR-200 family in tumor-associated stromal cells lead to cytokine production. Oncotarget, 2016 Jul 20.
  • Globally increased ultraconserved noncoding RNA expression in pancreatic ductal adenocarcinoma. Jiang, J., Azevedo-Pouly, A.C.P., Redis, R.S., Lee, E.J., Gusev, Y., Allard, D., Sutaria, S., Badawi, M., Elgamal, O.A., Brackett, D.J., Lerner, M.R., Calin, G.A. and Schmittgen, T.D. Oncotarget, 2016 Jun 23.
  • Rosas, L., Elgamal, O.A., Mo, X., Phelps, M.A., Schmittgen, T.D. and Papenfuss, T.C. In vitro Immunotoxicity Assessment of Culture-Derived Extracellular Vesicles in Human Monocytes. J. Immunotoxicol. 2016 Apr 14:1-14.
  • Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA. Li, B., Luo, X., Deng, B., McComb, D.W., Jiang, J., Schmittgen, T.D., and Dong, Y. Sci. Reports, 2016 Feb 26;6:22137.
  • Azevedo-Pouly, A.C.P., Elgamal, O.A and Schmittgen, T.D. RNA isolation from mouse pancreas, a ribonuclease-rich tissue. J. Vis. Exp., (90) e51779, 2014.
  • Elgamal,O.A., Park, J.K., Gusev, Y., Azevedo-Pouly, A.C., Jiang, J. Roopra, A., and Schmittgen, T.D. Tumor suppressive function of miR-205 in breast cancer is linked to HMGB3 regulation. PLoS One, 8:10, e764022013, 2013.
  • Park, J.K., Kogure, T., Nuovo, G.J., Jiang, J., Phelps, M.A., He, L., Kim, J.H., Croce, C.M., Patel, T., and Schmittgen, T.D. Silencing of miR-221 with anti-microRNA oligonucleotides is an effective therapeutic for hepatocellular carcinoma. Cancer Res., 71:7608-7616 (2011).

Google scholar: